These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38960976)

  • 1. Sample Size Determination and Study Design Impact on Dose-Scale Pharmacodynamic Bioequivalence: a Case Study Using Orlistat.
    Xu L; Li S; Wu W; Cheng Z; Xie F
    AAPS J; 2024 Jul; 26(4):77. PubMed ID: 38960976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.
    Di Marco M; Marier JF; Ducharme MP; Morin I; Engel C; Gulbranson S; Thudi NR; Murpani D; Rampal A; Monif T; Koundinya TS; Deo K; Monif T
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):319-26. PubMed ID: 18541129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic and Pharmacodynamic Equivalence of 2 Formulations of Orlistat.
    Johnson S; Schwartz SM
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):773-780. PubMed ID: 29659193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules.
    Zaid AN; Zohud N; E'layan B; Aburadi T; Jaradat N; Ali I; Hussein F; Ghanem M; Qaddomi A; Abu Zaaror Y
    Drug Des Devel Ther; 2017; 11():3291-3298. PubMed ID: 29200824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical aspects of bioequivalence testing between two medicinal products.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.
    Zhi J; Moore R; Kanitra L; Mulligan TE
    J Clin Pharmacol; 2002 Sep; 42(9):1011-9. PubMed ID: 12211217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short-Acting β-Agonist Formulations.
    Zeng Y; Singh S; Wang K; Ahrens RC
    J Clin Pharmacol; 2018 Apr; 58(4):457-465. PubMed ID: 29281130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.
    Diaz FJ; Berg MJ; Krebill R; Welty T; Gidal BE; Alloway R; Privitera M
    Clin Pharmacokinet; 2013 Dec; 52(12):1033-43. PubMed ID: 24085600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose bioequivalence: Exploration of eligible protocol design.
    Que L; Huang K; Ding Y; Chu N; Yang J; Qian Z; He Q
    J Clin Pharm Ther; 2021 Apr; 46(2):492-503. PubMed ID: 33325562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interchangeability of generic drugs for subpopulations: Bioequivalence simulation from a nonparametric PK model of gabapentin generic drugs.
    Glerum PJ; Yamada WM; Neely MN; Burger DM; Maliepaard M; Neef C
    Br J Clin Pharmacol; 2024 Jul; 90(7):1576-1585. PubMed ID: 36482842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the repeated cross-over designs in assessing bioequivalence.
    Liu JP
    Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A note on sample size determination for bioequivalence studies with high-order crossover designs.
    Chen KW; Chow SC; Li G
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
    Knahl SIE; Lang B; Fleischer F; Kieser M
    Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
    Zintzaras E; Bouka P
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.